Treatment Strategies with ICIs (Efficacy and Safety Data for SC Products)
Failed to add items
Sorry, we are unable to add the item because your shopping cart is already at capacity.
Add to basket failed.
Please try again later
Add to Wish List failed.
Please try again later
Remove from Wish List failed.
Please try again later
Follow podcast failed
Unfollow podcast failed
Treatment Strategies with ICIs (Efficacy and Safety Data for SC Products)
-
Narrated by:
-
By:
About this listen
- Atezolizumab and nivolumab are both FDA approved as SC products (pembrolizumab pending approval)
- Overall safety and efficacy of SC ICI products are similar to IV ICI counterpart therapies
- Patients receiving SC ICI may experience mild injection site reactions
- Clinical guidelines (NCCN) recommend
No reviews yet
In the spirit of reconciliation, Audible acknowledges the Traditional Custodians of country throughout Australia and their connections to land, sea and community. We pay our respect to their elders past and present and extend that respect to all Aboriginal and Torres Strait Islander peoples today.